Literature DB >> 19473080

Genotyping the GGGCGG tandem repeat promoter polymorphism in the 5-lipoxygenase enzyme gene (ALOX5) by pyrosequencing assay.

Anzeela M Schentrup1, Hooman Allayee, John J Lima, Julie A Johnson, Taimour Y Langaee.   

Abstract

AIMS: Efficient genotyping methods for many biologically significant repeat genetic polymorphisms, particularly in GC-rich regions of the genome, are limited. In particular, a short tandem repeat polymorphism [GGCGGG] in the promoter region of ALOX5 has been implicated as an important marker for inflammatory diseases. We developed a pyrosequencing assay to genotype the ALOX5 short tandem repeat polymorphism using pyrosequencing technology that will make assessing this important genetic marker in large, diverse populations more accessible than using current methods.
MATERIALS AND METHODS: We used a nested polymerase chain reaction approach to amplify DNA for pyrosequencing. Population allele frequencies were assessed in two cohorts of previously collected human DNA samples with 188 and 1032 samples, respectively. Sixteen genetic samples with known genotypes were used to confirm the accuracy of the method. RESULTS AND DISCUSSION: Genotypes were 100% concordant with samples of known genotype. Genotype frequencies in European American, Hispanic, and African American agreed with previously published results (wild-type homozygotes 66%, 64%, and 19%, respectively). The method presented here will facilitate both genetic association and pharmacogenomic research on this polymorphism in large samples that are ethnically and/or racially admixed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19473080      PMCID: PMC2998028          DOI: 10.1089/gtmb.2008.0103

Source DB:  PubMed          Journal:  Genet Test Mol Biomarkers        ISSN: 1945-0257


  23 in total

Review 1.  Genetic variation analyses by Pyrosequencing.

Authors:  Taimour Langaee; Mostafa Ronaghi
Journal:  Mutat Res       Date:  2005-06-03       Impact factor: 2.433

2.  Egr-1 and Sp1 interact functionally with the 5-lipoxygenase promoter and its naturally occurring mutants.

Authors:  E S Silverman; J Du; G T De Sanctis; O Rådmark; B Samuelsson; J M Drazen; T Collins
Journal:  Am J Respir Cell Mol Biol       Date:  1998-08       Impact factor: 6.914

3.  Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment.

Authors:  J M Drazen; C N Yandava; L Dubé; N Szczerback; R Hippensteel; A Pillari; E Israel; N Schork; E S Silverman; D A Katz; J Drajesk
Journal:  Nat Genet       Date:  1999-06       Impact factor: 38.330

4.  Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription.

Authors:  K H In; K Asano; D Beier; J Grobholz; P W Finn; E K Silverman; E S Silverman; T Collins; A R Fischer; T P Keith; K Serino; S W Kim; G T De Sanctis; C Yandava; A Pillari; P Rubin; J Kemp; E Israel; W Busse; D Ledford; J J Murray; A Segal; D Tinkleman; J M Drazen
Journal:  J Clin Invest       Date:  1997-03-01       Impact factor: 14.808

5.  Polymorphism of tandem repeat in promoter of 5-lipoxygenase in ASA-intolerant asthma: a positive association with airway hyperresponsiveness.

Authors:  S-H Kim; J-S Bae; C-H Suh; D-H Nahm; J W Holloway; H-S Park
Journal:  Allergy       Date:  2005-06       Impact factor: 13.146

6.  Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population.

Authors:  A Helgadottir; S Gretarsdottir; D St Clair; A Manolescu; J Cheung; G Thorleifsson; A Pasdar; S F A Grant; L J Whalley; H Hakonarson; U Thorsteinsdottir; A Kong; J Gulcher; K Stefansson; M J MacLeod
Journal:  Am J Hum Genet       Date:  2005-01-07       Impact factor: 11.025

7.  A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.

Authors:  Carl J Pepine; Eileen M Handberg; Rhonda M Cooper-DeHoff; Ronald G Marks; Peter Kowey; Franz H Messerli; Giuseppe Mancia; José L Cangiano; David Garcia-Barreto; Matyas Keltai; Serap Erdine; Heather A Bristol; H Robert Kolb; George L Bakris; Jerome D Cohen; William W Parmley
Journal:  JAMA       Date:  2003-12-03       Impact factor: 56.272

8.  Comparison of cytochrome P450 2C9 genotyping methods and implications for the clinical laboratory.

Authors:  Christina L Aquilante; Maximilian T Lobmeyer; Taimour Y Langaee; Julie A Johnson
Journal:  Pharmacotherapy       Date:  2004-06       Impact factor: 4.705

9.  The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke.

Authors:  Anna Helgadottir; Andrei Manolescu; Gudmar Thorleifsson; Solveig Gretarsdottir; Helga Jonsdottir; Unnur Thorsteinsdottir; Nilesh J Samani; Gudmundur Gudmundsson; Struan F A Grant; Gudmundur Thorgeirsson; Sigurlaug Sveinbjornsdottir; Einar M Valdimarsson; Stefan E Matthiasson; Halldor Johannsson; Olof Gudmundsdottir; Mark E Gurney; Jesus Sainz; Margret Thorhallsdottir; Margret Andresdottir; Michael L Frigge; Eric J Topol; Augustine Kong; Vilmundur Gudnason; Hakon Hakonarson; Jeffrey R Gulcher; Kari Stefansson
Journal:  Nat Genet       Date:  2004-02-08       Impact factor: 38.330

10.  Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis.

Authors:  James H Dwyer; Hooman Allayee; Kathleen M Dwyer; Jing Fan; Huiyun Wu; Rebecca Mar; Aldons J Lusis; Margarete Mehrabian
Journal:  N Engl J Med       Date:  2004-01-01       Impact factor: 91.245

View more
  2 in total

1.  Genetic variation in the lipoxygenase pathway and risk of colorectal neoplasia.

Authors:  Sarah E Kleinstein; Laura Heath; Karen W Makar; Elizabeth M Poole; Brenna L Seufert; Martha L Slattery; Liren Xiao; David J Duggan; Li Hsu; Karen Curtin; Lisel Koepl; Jill Muehling; Darin Taverna; Bette J Caan; Christopher S Carlson; John D Potter; Cornelia M Ulrich
Journal:  Genes Chromosomes Cancer       Date:  2013-02-12       Impact factor: 5.006

2.  Detection of three closely located single nucleotide polymorphisms in the EAAT2 promoter: comparison of single-strand conformational polymorphism (SSCP), pyrosequencing and Sanger sequencing.

Authors:  Shavanthi Rajatileka; Karen Luyt; Maggie Williams; David Harding; David Odd; Elek Molnár; Anikó Váradi
Journal:  BMC Genet       Date:  2014-07-05       Impact factor: 2.797

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.